Protein tyrosine phosphatase receptor type E (PTPRE) regulates the activation of wild-type KIT and KIT mutants differently.

GISTs KIT Mastocytosis Mutation PTPRE

Journal

Biochemistry and biophysics reports
ISSN: 2405-5808
Titre abrégé: Biochem Biophys Rep
Pays: Netherlands
ID NLM: 101660999

Informations de publication

Date de publication:
Jul 2021
Historique:
received: 13 12 2020
revised: 09 02 2021
accepted: 22 02 2021
entrez: 18 3 2021
pubmed: 19 3 2021
medline: 19 3 2021
Statut: epublish

Résumé

Activation of receptor tyrosine kinases needs tight control by tyrosine phosphatases to keep their normal function. In this study, we investigated the regulation of activation of the type III receptor tyrosine kinase KIT by protein tyrosine phosphatase receptor type E (PTPRE). We found that PTPRE can associate with wild-type KIT and inhibit KIT activation in a dose-dependent manner, although the activation of wild-type KIT is dramatically inhibited even when PTPRE is expressed at low level. The D816V mutation of KIT is the most frequently found oncogenic mutation in mastocytosis, and we found that PTPRE can associate and inhibit the activation of KIT/D816V in a dose dependent manner, but the inhibition is much weaker compared with wild-type KIT. Similar to mastocytosis, KIT mutations are the main oncogenic mutations in gastrointestinal stromal tumors (GISTs) although GISTs carry different types of KIT mutations. We further studied the regulation of the activation of GISTs-type KIT mutants and other mastocytosis-type KIT mutants by PTPRE. Indeed, PTPRE can almost block the activation of GISTs-type KIT mutants, while the activation of mastocytosis-type KIT mutants is more resistant to the inhibition of PTPRE. Taken together, our results suggest that PTPRE can associate with KIT, and inhibit the activation of both wild-type KIT and GISTs-type KIT mutants, while the activation of mastocytosis-type KIT mutants is more resistant to PTPRE.

Identifiants

pubmed: 33732906
doi: 10.1016/j.bbrep.2021.100974
pii: S2405-5808(21)00068-6
pmc: PMC7937656
doi:

Types de publication

Journal Article

Langues

eng

Pagination

100974

Informations de copyright

© 2021 The Authors.

Références

EMBO J. 1993 Nov;12(11):4199-209
pubmed: 7693453
Cell Biosci. 2020 Feb 12;10:16
pubmed: 32082541
Oncogene. 2005 Feb 3;24(6):1066-74
pubmed: 15690055
Oncol Lett. 2013 Feb;5(2):552-558
pubmed: 23420128
Physiol Rev. 2012 Oct;92(4):1619-49
pubmed: 23073628
Clin Cancer Res. 2002 Oct;8(10):3034-8
pubmed: 12374669
J Biol Chem. 2009 Apr 24;284(17):11039-47
pubmed: 19265199
Pharmacol Res. 2018 Jul;133:35-52
pubmed: 29704617
Cancer Res. 2003 May 1;63(9):2188-93
pubmed: 12727838
Endocrinology. 2008 Feb;149(2):605-14
pubmed: 18006633
J Biol Chem. 2003 Mar 14;278(11):9159-66
pubmed: 12511554
Cell Mol Life Sci. 2015 Nov;72(22):4399-407
pubmed: 26040420
Clin Rev Allergy Immunol. 2018 Jun;54(3):397-411
pubmed: 28725969
Mol Cancer Res. 2017 Sep;15(9):1265-1274
pubmed: 28584020
Clin Cancer Res. 2007 Mar 1;13(5):1367-73
pubmed: 17332278
Int J Mol Sci. 2015 Jul 09;16(7):15592-608
pubmed: 26184165
Clin Cancer Res. 2005 May 15;11(10):3668-77
pubmed: 15897563
Proc Natl Acad Sci U S A. 1999 Feb 16;96(4):1609-14
pubmed: 9990072
Cell Signal. 2017 Jan;29:138-149
pubmed: 27777072
Br J Haematol. 1998 Dec;103(3):740-9
pubmed: 9858225
J Cell Sci. 2014 Feb 1;127(Pt 3):653-62
pubmed: 24284075
Clin Cancer Res. 2003 Aug 15;9(9):3329-37
pubmed: 12960119
APMIS. 2007 Apr;115(4):289-98
pubmed: 17504295
Proc Natl Acad Sci U S A. 1995 Nov 7;92(23):10560-4
pubmed: 7479840
Hum Pathol. 2005 May;36(5):486-93
pubmed: 15948115
Lancet. 2013 Jan 26;381(9863):295-302
pubmed: 23177515
Am J Physiol Cell Physiol. 2010 Nov;299(5):C1144-52
pubmed: 20686073
Oncogene. 2014 Nov 13;33(46):5360-9
pubmed: 24213578
Front Pharmacol. 2020 Apr 14;11:443
pubmed: 32346366
Br J Cancer. 2006 Apr 24;94(8):1180-5
pubmed: 16570044

Auteurs

Shaoting Zhang (S)

Department of Pathogen Biology and Immunology, School of Basic Medical Sciences, Ningxia Medical University, No. 1160 Shengli Street, Yinchuan 750004, China.

Liangying Zhang (L)

Department of Pathogen Biology and Immunology, School of Basic Medical Sciences, Ningxia Medical University, No. 1160 Shengli Street, Yinchuan 750004, China.

Zongying Jiang (Z)

Department of Pathogen Biology and Immunology, School of Basic Medical Sciences, Ningxia Medical University, No. 1160 Shengli Street, Yinchuan 750004, China.

Yue Guo (Y)

Key Laboratory for Regenerative Medicine, Ministry of Education, School of Biomedical Sciences, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong SAR, China.

Hui Zhao (H)

Key Laboratory for Regenerative Medicine, Ministry of Education, School of Biomedical Sciences, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong SAR, China.

Jianmin Sun (J)

Department of Pathogen Biology and Immunology, School of Basic Medical Sciences, Ningxia Medical University, No. 1160 Shengli Street, Yinchuan 750004, China.
Department of Laboratory Medicine, Translational Cancer Research, Lund University, Lund, Sweden.

Classifications MeSH